| Literature DB >> 32101545 |
Joanna Tomlinson1, Johann Zwirner1, Benjamin Ondruschka2, Torsten Prietzel3,4, Niels Hammer1,4,5,6.
Abstract
The hip joint capsule contributes to the stability of the hip joint and lower extremity, yet this structure is incised and often removed during total hip arthroplasty (THA). Increasing incidence of osteoarthritis is accompanied by a dramatic rise in THAs over the last few decades. Consequently, to improve this treatment, THA with capsular repair has evolved. This partial restoration of physiological hip stability has resulted in a substantial reduction in post-operative dislocation rates compared to conventional THA without capsular repair. A further reason for the success of this procedure is thought to be the preservation of the innervation of the capsule. A systematic review of studies investigating the innervation of the hip joint capsular complex and pseudocapsule with histological techniques was performed, as this is not well established. The literature was sought from databases Amed, Embase and Medline via OVID, PubMed, ScienceDirect, Scopus and Web of Science; excluding articles without a histological component and those involving animals. A total of 21 articles on the topic were identified. The literature indicates two primary outcomes and potential clinical implications of the innervation of the capsule. Firstly, a role in the mechanics of the hip joint, as mechanoreceptors may be present in the capsule. However, the nomenclature used to describe the distribution of the innervation is inconsistent. Furthermore, the current literature is unable to reliably confirm the proprioceptive role of the capsule, as no immunohistochemical study to date has reported type I-III mechanoreceptors in the capsule. Secondly, the capsule may play a role in pain perception, as the density of innervation appears to be altered in painful individuals. Also, increasing age may indicate requirements for different strategies to surgically manage the hip capsule. However, this requires further study, as well as the role of innervation according to sex, specific pathology and other morphometric variables. Increased understanding may highlight the requirement for capsular repair following THA, how this technique may be developed and the contribution of the capsule to joint function and stability.Entities:
Year: 2020 PMID: 32101545 PMCID: PMC7043757 DOI: 10.1371/journal.pone.0229128
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1PRISMA flowchart of systematic review process.
Systematic review process, including databases, keywords, number of papers retrieved, inclusion and exclusion criteria and results from backwards and forwards searching [37].
Quality analysis of papers included in this review, using a modified quality assessment tool for histological observational studies, adapted from Knijn et al. (2015) and Manterola and Otzen (2017) [38, 39].
| Papers | Level of evidence | Is the hypothesis/ aim clear? | Does it indicate the number of samples studied? | Sample characteristics clearly described? | Are confounding variables between/within groups described? | Is the method for tissue retrieval clearly described? | Is the applied histological protocol clearly described? | Were methods to reduce bias described? | Does the study specify the statistical method employed? | Are the results presented clearly? | Are limitations and existing risk of bias described? | Is there a conclusion? | Total score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 | Y | Y | Y | Y | N | Y | N | Y | Y | N | Y | ||
| 4 | N | Y | Y | Y | N | Y | N | Y | Y | Y | Y | ||
| 4 | Y | Y | Y | Y | N | N | Y | N | N | Y | Y | ||
| 4 | Y | Y | N | N | Y | Y | Y | Y | Y | Y | Y | ||
| 4 | N | Y | Y | Y | N | Y | N | Y | Y | N | Y | ||
| 4 | N | Y | N | Y | Y | N | Y | Y | N | Y | Y | ||
| 4 | Y | Y | Y | N | Y | Y | N | N | Y | N | Y | ||
| 4 | N | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | ||
| 4 | Y | Y | Y | N | Y | Y | N | Y | Y | N | Y | ||
| 4 | N | Y | Y | N | Y | Y | N | Y | Y | N | Y | ||
| 4 | Y | Y | N | Y | N | Y | Y | Y | Y | N | Y | ||
| 4 | Y | Y | N | N | Y | Y | N | Y | Y | N | Y | ||
| 4 | N | Y | Y | N | Y | Y | N | N | Y | N | Y | ||
| 4 | N | Y | N | N | N | Y | N | Y | Y | Y | Y | ||
| 4 | Y | Y | Y | Y | Y | N | Y | N | Y | Y | Y | ||
| 4 | Y | Y | N | Y | N | Y | N | N | Y | N | N | ||
| 4 | Y | Y | Y | Y | Y | Y | Y | N | Y | N | N | ||
| 4 | Y | Y | Y | Y | N | Y | N | N | Y | N | N | ||
| 4 | N | N | N | N | N | N | N | N | N | N | N | ||
| 4 | N | Y | Y | N | N | N | N | N | N | N | N | ||
| 4 | N | Y | N | N | Y | Y | N | N | Y | N | Y |
Studies are listed in chronologically descending order and assessed to measure the risk of bias and quality of the study. One point was awarded for each question on the components of the study that was answered with a yes, to a maximum of eleven.
Demographic data of included groups from studies identified from the literature review.
| Author | Sample size | Sex ratio (male: female) | Age range | Tissue studied | Pathology studied |
|---|---|---|---|---|---|
| 80 | G1- 7:38 | G1- NS. Mean 27 years | Synovial membrane | G1- Moderate DDH and OA | |
| 15 | 6:9 | 37–83 years | Synovial membrane | OA | |
| 20 | NS | NS. Mean 76 years | Pseudocapsule | OA revision THA | |
| 30 | NS | G1- Preterm fetus | Capsule | G1- Fetus with NKP | |
| 34 | G1- 10:9 | G1- 5–18 years | Capsule | G1- CP and hip dislocation | |
| 57 patients | 29:28 | 8–87 years | G1- Capsule | AVN, CO, FAI, OA, SHD | |
| 8 | 5:3 | 68–93 years | Capsule | Mild to moderate OA (n = 5), severe OA (n = 3) | |
| 62 | G1- 4: 46 | G1- 48–80 years | Capsule | G1- OA | |
| 45 | 45:0 | G1- 38–75 years | Capsule, labrum, LHF | G1- OA | |
| 19 | 10:9 | 5–18 years | Capsule | CP and hip dislocation | |
| 15 | 7:8 | NS. Mean 67 years | Capsule and synovial membrane | Hip OA | |
| 9 | G1- 0:3 | G1- 74–75 years | G1- Capsule | G1- OA | |
| 6 | 0:6 | G1- 74–75 years | Capsule | G1- OA | |
| 22 | NS | NS | Capsule and synovial membrane | OA | |
| 20 | 12:8 | 6–20 months | Capsule | DDH | |
| 15 | G1- 2:2 | G1-1 66–75 | G1- Pseudocapsule G2- Capsule | G1-OA revision THA | |
| 8 | NS | NS. Mean 68 years | Pseudomembrane and capsule | AL | |
| 52 | G1- 5:0 | G1- 30–73 | Capsule and synovial membrane | G1- AS | |
| NS | NS | Fetus | Capsule | NS | |
| 56 | 34:22 | 30–55 years | Capsule | OA | |
| 2 | NS | NS | Capsule | NKP |
Studies are listed in chronologically descending order. Groups are labelled as G1, G2, etc. The abbreviations are related to the following pathologies, AL = aseptic loosening, AS = ankylosing spondylitis, AVN = avascular necrosis of the femoral head, CO = corrective osteotomy, CP = cerebral palsy, DDH = developmental dysplasia of the hip, FAI = femoroacetabular impingement, FNF = femoral neck fracture, IO = idiopathic osteonecrosis, LHF = ligament of the head of the femur, NKP = no known pathology, NS = not stated, OA = osteoarthritis, ON = osteonecrosis of femoral head, RA = rheumatoid arthritis, THA = total hip arthroplasty. Some studies investigated samples that were not relevant to the aims of this review, therefore they were not included in the results.
Table representing tissue origin, basic preparation and storage represented in the literature.
| Tissue from surgery | Tissue from cadavers | Decalcified | Paraffin embedded | Frozen tissue | |
|---|---|---|---|---|---|
Table representing details of the immunological markers for nerve tissue used in the current literature.
| Immunological markers | Antibody details |
|---|---|
| Chemicon International Inc., Temecula, CA, USA [ | |
| Rabbit antibody, 1:2000, Peninsula [ | |
| Rabbit antibody, 1:4000, Cambridge Research Biochemicals, Cambridge, UK [ | |
| 1:4000, Sigma Aldrich, St Louis, Missouri, USA [ | |
| Not stated [ | |
| Mouse monoclonal GAP-43/B-50, Chemicom International Inc., Temecula, CA, USA [ | |
| NF200, 1:1000, Abcam Inc, Cambridge, Massachusetts, USA [ | |
| NF200 [ | |
| Rabbit monoclonal 1:300, Novus Biologicals, Littleton, Colorado, USA [ | |
| Not stated [ | |
| Nuclear factor kß p65, Santa Cruz Biotechnology, Santa Cruz, CA, USA [ | |
| Anti NK1 antibody, details not specified [ | |
| Neurokinin 1, Sigma Aldrich, St Louis, Missouri, USA [ | |
| Rabbit polyclonal 1:500, Acris Antibodies GmbH, Germany [ | |
| Mouse polyclonal 1:1000, Abcam Inc. Cambridge, Massachusetts, USA [ | |
| Rabbit C-flanking peptide of neuropeptide Y antibody, 1:4000, Cambridge Research Biochemicals, Cambridge, UK [ | |
| Rabbit antibody, 1:6000, Cambridge Research Biochemicals, Cambridge, UK [ | |
| Monoclonal antibody [ | |
| Mouse monoclonal, Neomarkers, Fremont, California, USA [ | |
| Mouse monoclonal, 1:25, Novocastra, UK [ | |
| Rabbit monoclonal, 1:100, Acris Antibodies GmbH, Herford, Germany [ | |
| Rabbit anti-human RB9018P, Thermo Fisher Scientific, Waltham, MA, USA [ | |
| Polyclonal antibody, Immunon, Pittsburgh, USA [ | |
| Rabbit antibody, 1:4000, Cambridge Research Biochemicals, Cambridge, UK [ | |
| Rabbit monoclonal, 1:500, Acris Antibodies GmbH, Herford, Germany [ | |
| Rabbit polyclonal, 1:2000, Chemicon International Inc., Temecula, CA, USA [ | |
| Rabbit polyclonal, Ab1566, Chemicon International Inc., Temecula, CA, USA [ | |
| Rabbit Substance P, 1:500, ICN [ | |
| Substance P, INSTAR [ | |
| Not stated [ | |
| Anti—tyrosine hydroxylase, rabbit polyclonal, Ab152, Chemicon International Inc., Temecula, CA, USA [ | |
| Anti–tyrosine hydroxylase, 1:100, Millipore, Burlington, Massachusetts, USA [ | |
| Neuron specific class III ß-tubulin, Convance, Princeton, NJ, USA [ | |
| Rabbit antibody, 1:10,000, Cambridge Research Biochemicals, Cambridge, UK [ |
Several immunological markers were used to attempt to stain nerves and mechanoreceptors in the hip capsule, synovial membrane and the post-operative pseudocapsule. The full details of the antibodies were not stated in all papers. General nerve markers are S100, PGP 9.5, NF and TuJ-1. S100: Soluble protein 100, is noted to stain Schwann cells, NF = neurofilament, PGP 9.5 = protein gene product 9.5, TuJ-1 = Neuron specific tubulin stain the cell axon. Sensory nerve markers are SP, CGRP, NK1 and nociceptive. SP = substance P, CGRP = calcium gene-related peptide, nociception, NK1 = neurokinin 1. Sympathetic nerve markers are NY = Neuropeptide Y, TH = Tyrosine hydroxylase, VIP = vasoactive intestinal polypeptide. Nerve growth is marked by GAP. GAP: growth associated protein. Cellular response to painful stimuli is marked by NF-kß = nuclear factor kß.
Comparison of studies representing the immunohistochemical marker types, tissue type and nerve tissue structures noted in literature.
| Papers | Sample—Disease | General nerve marker | Sensory nerve marker | Sympathetic nerve marker | |||
|---|---|---|---|---|---|---|---|
| DDH and OA | nf | nf | |||||
| OA | nf | nf | nf | ||||
| DDH | FNE | ||||||
| NKP | FNE | ||||||
| 2 THA | FNE | ||||||
| CP | nf | nf | |||||
| DDH | nf | nf | |||||
| 1 THA | nf, FNE | nf, FNE | nf, FNE | ||||
| FNF | None noted | None noted | |||||
| OA | nf | nf | |||||
| CP | nf, FNE | nf, FNE | |||||
| OA | N | nf | N | nf | |||
| FNF | nf, FNE | ||||||
| OA | nf | ||||||
| Pain-free failed THA | None noted | ||||||
| OA | nf | ||||||
| FNF | nf | ||||||
| DDH | None noted | ||||||
| OA | nf | nf | nf | nf | |||
| OA 1 THA | nf | nf | nf | ||||
| OA 2 THA AL | nf, FNE | nf | nf | ||||
| OA 2 THA AL | nf | ||||||
| Capsular ligament | |||||||
| Synovium | |||||||
| Pseudocapsule | |||||||
General nerve markers include S100, neurofilament protein, PGP 9.5 and neuron specific tubulin. Sensory nerve markers included are substance P, calcitonin gene-related peptide and nociceptin. Sympathetic nerve markers include neuropeptide Y, tyrosine hydroxylase, C-flanking peptide of neuropeptide Y and vasoactive intestinal polypeptide. FNE = free nerve ending, nf = nerve fibre, AL = aseptic loosening, CP = cerebral palsy, DDH = developmental dysplasia of the hip joint, FNF = fractured neck of femur, NKP = no known pathology, OA = osteoarthritis, THA = total hip replacement, the 1 and 2 refer to primary and secondary.
Fig 2Diagram demonstrating the general agreement of innervation by mechanoreceptors I-V across the hip joint capsule.
(A) Anterior view of the left side, representing increased expression laterally and superior-laterally. (B) posterior view of the left side, showing increased expression laterally. Darker regions depict areas where the literature demonstrates greater agreement of higher density of innervation. Lighter areas are regions of general agreement of little to no innervation. D = distal, I = inferior, L = lateral, M = medial, P = proximal, S = superior. ASIS = anterior superior iliac spine, AIIS = anterior inferior iliac spine.